Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Rayzzeron Mar 12, 2018 7:02pm
274 Views
Post# 27703634

RE:Welcome all newcomers

RE:Welcome all newcomersNewcomers may also like to view this research report from Zacks SCR. The report currently values the company at $0.85 per share. Keep in mind this valuation is very conservative and uses these assumptions:

1. based on only one ( ATB-346 ) of 3 drugs in the pipeline.
2. based on only one approved indication - osteoarthritis
3. based on only 6% market share in the USA and EU of the one indication
4. based on a 50% chance of approval


https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/VATE-Final-Subject-Enrolled-in-Phase-2b-Trial-of-ATB-346-Data-Expected-in-March-2018-article/



StrikingMoose wrote: I knew this day would come!

The most important DD you can do in this company is watch this video of the scientific head speaking to a group of doctors about their drug pipeline

https://www.youtube.com/watch?v=w_3heP7ol0A


Review the science team and see how great they are.

They have enough money to make it through the next trial.

They are planning partnership agreements IMMEDIATELY after the results of this upcoming trial.

The next 2 weeks should be life changing for anyone holding!


Bullboard Posts